Results 221 to 230 of about 1,522,764 (280)

Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma. [PDF]

Mol Cancer
Zhao Z, Zheng W, He Y, Zhang H, Zhang L, Huo Y, Jiang J, Zhang C, Lyu H, Qin W, Liu C, Chang F, Shan L, Wang T, Song W.   +14 more
europepmc   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source

Anti-MSLN chimeric antigen receptor-like NK cell therapy with tumor-penetrating capacity (uCAR-like NK) for solid tumors. [PDF]

Signal Transduct Target Ther
An M, Wang Y, Shao J, Wu S, Yan J, Li Y, Zhong L, Guo J, Chen T, Tian M, Liu Q, Li R, Liu B.   +12 more
europepmc   +1 more source

Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model. [PDF]

Int J Mol Sci
Emelianov EA, Naberezhnaya ER, Logvinov AS, Stepanova VM, Chernov AS, Mokrushina YA, Malabuiok DM, Pershin DE, Malakhova EA, Kulakovskaya EA, Prokofeva TN, Tatarskiy VV, Shramova EI, Deyev SM, Gabibov AG, Kushlinskii NE, Rubtsov YP, Volkov DV.   +17 more
europepmc   +1 more source

A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer. [PDF]

Int J Mol Sci
Jin W, Wang M, Wang J, Fan J, Fang J, Yang G.   +5 more
europepmc   +1 more source

Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets. [PDF]

Hemasphere
Dingfelder J, Aigner M, Lindacher J, Lukas P, Flamann C, Nusser G, Zimmermann K, Schambach A, Graw F, Völkl S, Bruns H, Krumbholz M, Haibach M, Wilke J, Mackensen A, Lutzny-Geier G.   +15 more
europepmc   +1 more source

CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies. [PDF]

Signal Transduct Target Ther
Shu P, Guo F, Qin D, Zou L, Ma Q, Zhang B, Gao G, Chen Y, He X, Jiang M, Liu N, Zhou K, Zhao J, Lei Y, Gao Y, Zhang Y, Zeng Y, Feng M, Li X, Li D, Wang Y.   +20 more
europepmc   +1 more source